COMPANY PROFILE

Simcha Therapeutics

Explore full profile

Developing engineered cytokine immunotherapy for cancer

New Haven, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Simcha Therapeutics

Simcha Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of cytokine immunotherapies for cancer treatment. The company's core technology revolves around engineering cytokines, which are proteins crucial for immune system signaling, to be more effective in fighting tumors.

Their lead product candidate, ST-067, is an engineered form of Interleukin-18 (IL-18) designed to be "decoy-resistant." This modification allows it to overcome a common mechanism by which tumors evade the immune system, thus restoring the body's natural anti-tumor activity. The company is advancing ST-067 through clinical trials, including a collaboration with Merck to evaluate it in combination with KEYTRUDA® (pembrolizumab).

Simcha Therapeutics operates on a biopharmaceutical research and development model, aiming to bring its novel therapies to market. The company was founded based on technology developed at the Yale School of Medicine, with which it maintains a research and option agreement. Its primary clients are patients with various forms of cancer who may benefit from immunotherapy.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: New Haven, United States
Employees: 11
Open positions: None listed
Dealroom signal: 62.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jan 2022	$40M	$160M	BVF Partners · ArrowMark Partners · Rock Springs Capital · Samsara BioCapital	↗
SERIES AOther financing	Jun 2020	$25M	$100M	Sequoia · WuXi AppTec · Connecticut Innovations · Wuxi Venture Capital Group	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Simcha Therapeutics website traffic

Latest recorded traffic for Simcha Therapeutics is 3.3K monthly website visits, up 73.7% over the last three months. Simcha Therapeutics's team declined 21.4% over the past year.

Latest monthly visits3.3K 3-month web change+73.7% 1-year team growth-21.4%

Monthly website visitsJul 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
KTKelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform	Boston, United States	Acquired	65	$50M	$3.3B
MTMapLight TherapeuticsPrecision neuroscience developing targeted therapies for serious brain disorders	Redwood City, United States	Operational
NENeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment	Kearny, United States	Operational
PHPharmCADDCombines deep learning approaches with molecular dynamics simulation and quantum calculation to create cutting-edge computational modules	Busan, South Korea	Operational
DBDebut BiotechCreating advanced continuous manufacturing approaches for the production of small and large molecules harnessing the power of biocatalysis	San Diego, United States	Operational
VTVerve TherapeuticsFocused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary	Cambridge, United States	Acquired
EBEV BiotechMicrobial cell factory (MCF) strain development company	Groningen, Netherlands	Operational
DRDrugBankAI-powered pharmaceutical knowledge platform for drug development	Edmonton, Canada	Operational